RNAC
Income statement / Annual
Last year (2023), Cartesian Therapeutics, Inc.'s total revenue was $26.00 M,
a decrease of 76.53% from the previous year.
In 2023, Cartesian Therapeutics, Inc.'s net income was -$219.71 M.
See Cartesian Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$26.00 M
|
$110.78 M
|
$85.08 M
|
$16.60 M
|
$6.68 M
|
$903,000.00
|
$207,000.00
|
$8.08 M
|
$6.01 M
|
| Cost of Revenue |
$1.55 M |
$2.04 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$24.45 M |
$108.74 M |
$85.08 M |
$16.60 M |
$6.68 M |
$903,000.00 |
$207,000.00 |
$8.08 M |
$6.01 M |
| Gross Profit Ratio |
0.94 |
0.98 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
| Research and Development
Expenses |
$71.84 M
|
$72.38 M
|
$68.74 M
|
$54.51 M
|
$42.74 M
|
$47.69 M
|
$45.17 M
|
$29.70 M
|
$22.98 M
|
| General & Administrative
Expenses |
$40.58 M
|
$23.86 M
|
$20.94 M
|
$18.91 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$40.58 M
|
$23.86 M
|
$20.94 M
|
$18.91 M
|
$14.36 M
|
$17.26 M
|
$18.08 M
|
$12.25 M
|
$7.29 M
|
| Other Expenses |
$0.00 |
$330,000.00 |
$15,000.00 |
$89,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$110.87 M |
$96.24 M |
$89.67 M |
$73.42 M |
$57.11 M |
$64.95 M |
$63.24 M |
$41.95 M |
$30.27 M |
| Cost And Expenses |
$112.42 M |
$96.24 M |
$89.67 M |
$73.42 M |
$59.13 M |
$65.93 M |
$63.99 M |
$42.75 M |
$31.32 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$834,000.00 |
$1.05 M |
$617,000.00 |
$234,000.00 |
$171,000.00 |
| Interest Expense |
$2.83 M |
$3.03 M |
$2.84 M |
$1.56 M |
$1.52 M |
$1.49 M |
$1.21 M |
$1.25 M |
$948,000.00 |
| Depreciation &
Amortization |
$843,000.00
|
$2.04 M
|
$1.72 M
|
$1.73 M
|
$2.03 M
|
$975,000.00
|
$750,000.00
|
$802,000.00
|
$1.04 M
|
| EBITDA |
-$235.06 M
|
$39.84 M
|
-$5.16 M
|
-$65.59 M
|
-$51.80 M
|
-$62.87 M
|
-$63.37 M
|
-$34.16 M
|
-$23.18 M
|
| EBITDA Ratio |
-9.04 |
0.15 |
-0.04 |
-3.37 |
-7.55 |
-70.93 |
-304.51 |
-4.19 |
-4.04 |
| Operating Income Ratio
|
-3.32
|
0.13
|
-0.05
|
-3.42
|
-7.86
|
-72.01
|
-308.14
|
-4.29
|
-4.21
|
| Total Other
Income/Expenses Net |
-$152.29 M
|
$20.23 M
|
-$5.12 M
|
-$12.06 M
|
-$2.90 M
|
-$314,000.00
|
-$1.54 M
|
-$1.54 M
|
$130,000.00
|
| Income Before Tax |
-$238.71 M |
$34.77 M |
-$9.72 M |
-$68.88 M |
-$55.35 M |
-$65.34 M |
-$65.32 M |
-$36.21 M |
-$25.17 M |
| Income Before Tax Ratio
|
-9.18
|
0.31
|
-0.11
|
-4.15
|
-8.29
|
-72.35
|
-315.56
|
-4.48
|
-4.19
|
| Income Tax Expense |
-$19.00 M |
-$609,000.00 |
$15.97 M |
$1.65 M |
$1.86 M |
$1.00 |
$0.00 |
$0.00 |
$0.00 |
| Net Income |
-$219.71 M |
$35.38 M |
-$25.69 M |
-$68.88 M |
-$55.35 M |
-$65.34 M |
-$65.32 M |
-$36.21 M |
-$25.17 M |
| Net Income Ratio |
-8.45 |
0.32 |
-0.3 |
-4.15 |
-8.29 |
-72.35 |
-315.56 |
-4.48 |
-4.19 |
| EPS |
-42.49 |
7.33 |
-6.74 |
-20.42 |
-36.46 |
-87.55 |
-95.94 |
-103.52 |
-40.5 |
| EPS Diluted |
-42.49 |
2.98 |
-6.74 |
-20.42 |
-36.46 |
-87.55 |
-95.94 |
-103.52 |
-40.5 |
| Weighted Average Shares
Out |
$5.17 M
|
$4.83 M
|
$3.81 M
|
$3.37 M
|
$1.52 M
|
$746,309.00
|
$680,834.00
|
$349,797.00
|
$621,652.00
|
| Weighted Average Shares
Out Diluted |
$5.17 M
|
$4.86 M
|
$3.81 M
|
$3.37 M
|
$1.52 M
|
$746,309.00
|
$680,834.00
|
$349,797.00
|
$621,652.00
|
| Link |
|
|
|
|
|
|
|
|
|
